Click Here to View the Activity
This educational activity is specifically designed for hematologists, internists, oncologists and other physicians, physicians-in-training, and healthcare professionals (nurses, pharmacists) interested in and/or involved in the care of patients with myeloproliferative diseases and myelodysplastic syndromes.
The 4th International Congress of Myeloproliferative Diseases and Myelodysplastic Syndromes, chaired by Dr Richard Silver and co-chaired by Dr Jerry Spivak, was held on November 8-10, 2007 in Brooklyn, New York and drew on the expertise of 28 internationally known leaders in the fields of molecular biology, pathology, immunology, and translational and clinical research to lead the discussion on the cutting edge topics in this field. This Webcast is an online representation of the entire congress and provides a stimulating program for all those who are interested in normal and dysfunctional myeloid cell development, trafficking, pathology, and treatment.
After completing this activity, the participant will be able to:
- Recognize the molecular mechanisms, biology, and drug targets of the myelodysplastic syndromes (MDS) and myeloproliferative diseases (MPD)
- Translate current controversies in management of MDS and MPD into improved patient outcomes
- Implement new treatment modalities in MDS and MPD
- Review the latest updates in overcoming drug resistance for MDS and MPD
- Discuss the pipeline of novel agents for MDS and MPD and their impact on future patient care
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), Imedex®, LLC must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Faculty are encouraged to provide a balanced view of therapeutic options including but not limited to the use of generic names to ensure impartiality.
All faculty participating in an Imedex activity are required to disclose commitments to and/or relationships with pharmaceutical companies, biomedical device manufacturers or distributors, or others whose products or services may be considered to be related to the subject matter of the educational activity. Disclosure of these commitments and/or relationships is included in these course materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
The following indicates the faculty disclosure declaration information and the nature of those commercial relationships.
1=grant/research support 2=consultant 3=speaker’s bureau 4=stock shareholder 5=other support
| Jorge Cortes, MD |
Breakthrough Therapeutics, LLC1; ChemGenex Pharmaceuticals1; The Vaccine Company L.P.1; Tibotec Pharmaceuticals Limited1; Wyeth Pharmaceuticals, Inc.1 |
| H. Joachim Deeg, MD |
PDL BioPharma, Inc.1 |
| Michael Deininger, MD, PhD |
Calistoga1; SGX Pharmaceuticals, Inc.1 |
| Anthony R. Green, PhD, FRCP, FRC |
Astex Therapeutics Limited2; AstraZeneca Pharmaceuticals LP2; Incyte Corporation2 |
| Rudiger Hehlmann, MD, PhD |
Roche Laboratories Inc.1; Schering-Plough Corporation1 |
| Ronald Hoffman, MD |
AstraZeneca Pharmaceuticals LP2; U.S. Department of Defense1; National Cancer Institiute1 |
| Alan F. List, MD |
Kanisa Pharmaceuticals, Inc.5; Scios, Inc.1,2 |
| Gail J. Roboz, MD |
Cephalon, Inc1,5 |
| Radek Skoda, MD |
Genentech BioOncology3 |
The following speakers have reported an affiliation with the supporters of this conference:
| Jorge Cortes, MD |
Bristol-Myers Squibb Company1; Novartis Pharmaceuticals Corporation1; MERCK & CO., Inc1 |
| Nick C.P. Cross, MA, PhD, FRCPath |
Bristol-Myers Squibb Company3; Novartis Pharmaceuticals Corporation3 |
| H. Joachim Deeg, MD |
Genzyme Corporation2; Pharmion Corporation1 |
| Michael Deininger, MD, PhD |
Bristol-Myers Squibb Company2; Novartis Pharmaceuticals Corporation1 |
| John Goldman, MD |
Bristol-Myers Squibb Company3; Novartis Pharmaceuticals Corporation3 |
| Anthony R. Green, PhD, FRCP, FRCPath |
Bristol-Myers Squibb Company3; Shire Pharmaceuticals2 |
| Rudiger Hehlmann, MD, PhD |
Bristol-Myers Squibb Company2; Novartis Pharmaceuticals Corporation1,2 |
| Ronald Hoffman, MD |
MERCK & CO., Inc.1 |
| Hagop M. Kantarjian, MD |
Bristol-Myers Squibb Company1; Novartis Pharmaceuticals Corporation1; MGI PHARMA, INC.1 |
| Alan F. List, MD |
Celgene Corporation1,2,3 |
| Giuseppe Saglio, MD |
Bristol-Myers Squibb Company3; Novartis Pharmaceuticals Corporation3 |
| Richard T. Silver, MD, FACP |
Bristol-Myers Squibb Company1,2,3; Celgene Corporation1; Novartis Pharmaceuticals Corporation1 |
The following speakers do not report any affiliation:
Tiziano Barbui, MD
Giovanni Barosi, MD
John M. Bennett, MD
Francisco Cervantes, MD
D. Gary Gilliland, MD, PhD
Chloe James, MD
Marie-Caroline Le Bousse-Kerdilès, PhD
Ruben A. Mesa, MD
Alison R. Moliterno, MD
Attilio Orazi, MD
Vesna Najfeld, PhD
Heike L. Pahl, PhD
Josef T. Prchal, MD
Charles L. Sawyers, MD
Jerry L. Spivak, MD, FACP
Ayalew Tefferi, MD
All materials are included with the permission of the authors.
All Imedex staff members who are in a position to control the content of this activity have no financial relationships with any commercial interests that are relevant to this activity.
Tiziano Barbui, MD
Ospedali Riuniti di Bergamo
Bergamo, Italy
Giovanni Barosi, MD
IRCCS Policlinico San Matteo
Pavia, Italy
John M. Bennett, MD
University of Rochester Medical Center
Rochester, New York
Peter Campbell, MD
Cambridge Institute for Medical Research
Cambridge, United Kingdom
Francisco Cervantes, MD
Hospital Clinic, University of Barcelona
Barcelona, Spain
Jorge Cortes, MD
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas
Nick C.P. Cross, MA, PhD, FRCPath
University of Southampton School of Medicine
Wilts, United Kingdom
H. Joachim Deeg, MD
Fred Hutchinson Cancer Research Center
Seattle, Washington
Michael Deininger, MD, PhD
Oregon Health & Science University Cancer Institute
Portland, Oregon
D. Gary Gilliland, MD, PhD
Brigham and Women’s Hospital
Boston, Massachusetts
John Goldman, MD
Hammersmith Hospital
Imperial College London
London, United Kingdom
Anthony R. Green, PhD, FRCP, FRCPath
Cambridge Institute for Medical Research
Addenbrooke’s Hospital
Cambridge, United Kingdom
Rudiger Hehlmann, MD, PhD
Klinikum Mannheim der Universität
Heidelberg Mannheim
Mannheim, Germany
Ronald Hoffman, MD
Mount Sinai School of Medicine
New York, New York
Chloe James, MD
INSERM U876
Universite Bordeaux 2
Bordeaux, France
|
Hagop M. Kantarjian, MD
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas
Marie-Caroline Le Bousse-Kerdilès, PhD
INSERM U602
Villejuif, France
Alan F. List, MD
H. Lee Moffitt Cancer Center
and Research Institute
Tampa, Florida
Ruben A. Mesa, MD
Mayo Clinic
Rochester, Minnesota
Alison R. Moliterno, MD
Johns Hopkins University School of Medicine
Baltimore, Maryland
Vesna Najfeld, PhD
Mount Sinai Medical Center
New York, New York
Attilio Orazi, MD
Indiana University School of Medicine
Indianapolis, Indiana
Heike L. Pahl, PhD
University Hospital Freiburg
Freiburg, Germany
Josef T. Prchal, MD
University of Utah Health Sciences Center
Salt Lake City, Utah
Gail J. Roboz, MD
Weill Medical College of Cornell University
New York, New York
Giuseppe Saglio, MD
University of Turin
Hospital San Luigi Gonzaga
Orbassano-Torino, Italy
Charles L. Sawyers, MD
Memorial Sloan-Kettering Cancer Center
New York, New York
Richard T. Silver, MD, FACP
Weill Medical College of Cornell University
New York, New York
Radek Skoda, MD
University Hospital Basel
Basel, Switzerland
Jerry L. Spivak, MD, FACP
Johns Hopkins University School of Medicine
Baltimore, Maryland
Ayalew Tefferi, MD
Mayo Clinic
Rochester, Minnesota
|
This activity is sponsored by Imedex, LLC.
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Imedex, LLC designates this educational activity for a maximum of 17.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
In order to receive credit, participants must successfully complete the post-test and complete the online evaluation form. You will receive an online CME statement of credit to print for your records.
For questions regarding the accreditation of this activity, please contact
Imedex
4325 Alexander Drive
Alpharetta, GA 30022
Fax: +1(770) 751-7334
Email: enduring@imedex.com
This Webcast may contain information about experimental and other uses of drugs or devices that are not currently approved by the US Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.
The opinions expressed in this Webcast are the opinions of the authors and do not necessarily reflect the opinions of Imedex or the American School of Oncology.
The following companies have provided unrestricted educational grants in support of this activity:
Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Genzyme Corporation; MERCK & CO., Inc; MGI PHARMA, INC.; Novartis Pharmaceuticals Corporation; Pharmion Corporation; and Shire PLC.
Click Here to View the Activity |
